3-(6-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)hexyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide | 1424337-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 3-(6-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)hexyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
• 英文别名: 3-[6-[[2-[tert-butyl(dimethyl)silyl]oxy-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethyl]amino]hexoxy]-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
• CAS: 1424337-30-3
• 化学式: C₃₇H₅₁Cl₂N₃O₆Si
• 分子量: 732.82
• InChiKey: ORSVXRHNUDZAHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.59
• 重原子数：
  49
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-(6-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)hexyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide 在 盐酸 、 氟化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 60.0h， 生成 N-(3,5-dichloropyridin-4-yl)-3-[6-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexoxy]-4-methoxybenzamide
  参考文献：
  名称：

  Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

  摘要：

  A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50) = 8.47-9.20) than the reference compound salmeterol (pEC(50) = 8.3) and good inhibitory activity on PDE4B2 (IC50 = 0.235-1.093 mu M). (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.058
• 作为产物：
  描述：

  2-溴-1-(2,2-二甲基-4H-1,3-苯并二噁英-6-基)乙酮 在 咪唑 、 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 41.0h， 生成 3-(6-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)hexyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
  参考文献：
  名称：

  Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

  摘要：

  A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50) = 8.47-9.20) than the reference compound salmeterol (pEC(50) = 8.3) and good inhibitory activity on PDE4B2 (IC50 = 0.235-1.093 mu M). (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.058

文献信息

• Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD
  作者：Anqiu Liu、Ling Huang、Zhiren Wang、Zonghua Luo、Fei Mao、Wenjun Shan、Jiaxing Xie、Kefang Lai、Xingshu Li

  DOI：10.1016/j.bmcl.2012.11.058

  日期：2013.3

  A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50) = 8.47-9.20) than the reference compound salmeterol (pEC(50) = 8.3) and good inhibitory activity on PDE4B2 (IC50 = 0.235-1.093 mu M). (c) 2012 Elsevier Ltd. All rights reserved.